<DOC>
	<DOCNO>NCT02354209</DOCNO>
	<brief_summary>The purpose study look possible reason HIV positive people take drug properly resistance drug , still low amount virus detectable blood . This know Low Level Viraemia ( LLV ) . When low level HIV virus present , mutate make drug less effective ( i.e . variant virus become resistant ) . Currently , however , resistance mutation may difficult detect use standard test resistance amount virus blood low standard test n't sensitive enough pick mutation . The investigator use sensitive mutation detection method , know Next Generation Sequencing ( NGS ) , look whether see low level drug resistant HIV virus develop blood LLV occur . The investigator look different treatment strategy use routine standard practice LLV detect evaluate effective preventing development resistance . The investigator hope research help inform guideline best way treat HIV future .</brief_summary>
	<brief_title>Targeted Clinical Strategies Low Level Viraemia ( LLV ) Boosted Protease Inhibitor Therapy</brief_title>
	<detailed_description>Phase Study : Non-Drug Study Objectives : 1 . Primary To investigate cause low level viraemia ( LLV ) HIV-infected individual PI resistance associate mutation ( RAMs ) conventional genotyping detectable plasma HIV viral load ( pVL ) report &gt; 95 % adherence* ARV regimens contain boost protease inhibitor . *in case questionnaire perform , clinical documentation adherence use interpretation adherence level . 2 . Secondary To observe evolution virologic immunologic response follow routine clinical intervention HIV-infected individual primary protease inhibitor mutation ( IAS , USA ) conventional genotyping detectable plasma HIV viral load ( pVL ) report &gt; 95 % adherence* antiretroviral regimen contain boost protease inhibitor . - case questionnaire perform , clinical documentation adherence use interpretation adherence level . Study Design : A multi-centre , non-drug , observational cohort study . Methodology : HIV-infected individual attend three select HIV clinic Chelsea Westminster Hospital , St Mary 's Hospital Guy 's St Thomas ' Hospital duration study identify weekly viral resistance meeting routine clinic appointment demonstrate follow HIV pVL criterion : 1 . An HIV pVL 41-2000 copies/ml ( c/ml ) two consecutive test &lt; 40 c/ml least two occasion bPI-containing regimen 2 . An HIV pVL 41-2000 c/ml two consecutive test never achieve &lt; 40 c/ml bPI-containing regimen six month treatment . Eligible patient provide patient information sheet write consent form . Following consent : 1 . Virologic immunologic assessment collect clinical record available 2 . Viral resistance test ( VRT ) ( use VircoTYPE HIV-1 Virtual PhenotypeTM-LM conventional genotyping Ilumina MiSeq next generation sequencing , NGS minority specie test ) perform first detectable HIV pVL ( &gt; 40 c/mL ) find clinic 3 6 12 month later , HIV pVL still &gt; 40 c/mL . Planned Sample Size : 120 240 sample one-year study period , centre provide 40 80 sample . Summary Eligibility Criteria : HIV-infected individual primary protease inhibitor mutation ( IAS , USA ) standard VRTs detectable pVL report &gt; 95 % adherence* ARV regimens contain boost protease inhibitor HIV VL criterion detail . Individuals detectable HIV VL stop ARV 8-item Morisky score 2 ( &lt; 95 % report adherence eligible . *in case questionnaire perform , clinical documentation adherence use interpretation adherence level . Number Study Centres : Three Duration Study : One year study approval . Samples resistance test collect duration study . Criteria Evaluation : 1 . Emergence new primary protease inhibitor mutation ( IAS , USA ) use NGS described . 2 . Comparison respective parameter ( HIV VL CD4 count ) different clinical intervention . The latter dictate protocol conduct routine clinical practice . Primary Endpoint : Development primary protease inhibitor mutation ( IAS , USA ) NGS HIV-infected patient primary protease inhibitor mutation ( IAS , USA ) standard VRTs demonstrate LLV ARV regimens contain bPI . Secondary Endpoints : 1 . Proportion patient achieve undetectable HIV VL follow intervention period LLV ARV regimens contain bPI 2 . Evolution CD4 cell count follow intervention period LLV ARV regimens contain bPI . Note : This non-drug study intervention dictate protocol .</detailed_description>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>A subject eligible inclusion study ALL follow criterion apply : 1 . Chronic HIV1 infection ( adult male , female transgender ) 2 . Age &gt; 18 year 3 . Current HIV clinic attendee Chelsea Westminster Hospital , St Mary 's Hospital , Guy 's St Thomas ' Hospital [ define least 1 attend clinic visit since January 2010 ] 4 . Receiving boost protease inhibitorcontaining antiretroviral regimen ( bPI ARV ) 5 . HIV plasma viral load ( pVL ) 412000 copies/ml ( c/ml ) two consecutive test &lt; 40 c/ml least two occasion bPIcontaining regimen OR HIV pVL 412000 c/ml two consecutive test never achieve &lt; 40 c/ml bPI contain regimen six month treatment . A subject NOT eligible inclusion clinical trial follow criterion apply : 1 . Demonstrable detectable HIV VL stop ARV 2 . 8item Morisky score 2 documented poor adherence combination ARV . ( &lt; 95 % adherence* ) case questionnaire perform , clinical documentation adherence use interpretation adherence level</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>